Logo image of EHAB

ENHABIT INC (EHAB) Stock Fundamental Analysis

NYSE:EHAB - New York Stock Exchange, Inc. - US29332G1022 - Common Stock - Currency: USD

8.14  -0.3 (-3.55%)

After market: 8.14 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to EHAB. EHAB was compared to 108 industry peers in the Health Care Providers & Services industry. EHAB may be in some trouble as it scores bad on both profitability and health. EHAB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year EHAB was profitable.
In the past year EHAB had a positive cash flow from operations.
In multiple years EHAB reported negative net income over the last 5 years.
Each year in the past 5 years EHAB had a positive operating cash flow.
EHAB Yearly Net Income VS EBIT VS OCF VS FCFEHAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M

1.2 Ratios

With a Return On Assets value of -8.94%, EHAB is not doing good in the industry: 69.16% of the companies in the same industry are doing better.
EHAB has a Return On Equity of -20.60%. This is in the lower half of the industry: EHAB underperforms 62.62% of its industry peers.
With a Return On Invested Capital value of 2.65%, EHAB perfoms like the industry average, outperforming 47.66% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for EHAB is below the industry average of 8.14%.
Industry RankSector Rank
ROA -8.94%
ROE -20.6%
ROIC 2.65%
ROA(3y)-0.53%
ROA(5y)N/A
ROE(3y)-3.22%
ROE(5y)N/A
ROIC(3y)5%
ROIC(5y)N/A
EHAB Yearly ROA, ROE, ROICEHAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 5 -5 -10

1.3 Margins

EHAB has a Operating Margin (3.75%) which is comparable to the rest of the industry.
In the last couple of years the Operating Margin of EHAB has declined.
EHAB's Gross Margin of 48.79% is fine compared to the rest of the industry. EHAB outperforms 76.64% of its industry peers.
EHAB's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 3.75%
PM (TTM) N/A
GM 48.79%
OM growth 3Y-27.36%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.9%
GM growth 5YN/A
EHAB Yearly Profit, Operating, Gross MarginsEHAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 20 40

More info and screens

3

2. Health

2.1 Basic Checks

EHAB has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for EHAB remains at a similar level compared to 1 year ago.
The debt/assets ratio for EHAB is higher compared to a year ago.
EHAB Yearly Shares OutstandingEHAB Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 10M 20M 30M 40M 50M
EHAB Yearly Total Debt VS Total AssetsEHAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 500M 1B 1.5B

2.2 Solvency

EHAB has an Altman-Z score of 1.44. This is a bad value and indicates that EHAB is not financially healthy and even has some risk of bankruptcy.
EHAB's Altman-Z score of 1.44 is on the low side compared to the rest of the industry. EHAB is outperformed by 62.62% of its industry peers.
The Debt to FCF ratio of EHAB is 9.54, which is on the high side as it means it would take EHAB, 9.54 years of fcf income to pay off all of its debts.
EHAB's Debt to FCF ratio of 9.54 is fine compared to the rest of the industry. EHAB outperforms 60.75% of its industry peers.
EHAB has a Debt/Equity ratio of 0.89. This is a neutral value indicating EHAB is somewhat dependend on debt financing.
EHAB has a Debt to Equity ratio of 0.89. This is in the lower half of the industry: EHAB underperforms 63.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF 9.54
Altman-Z 1.44
ROIC/WACC0.3
WACC8.77%
EHAB Yearly LT Debt VS Equity VS FCFEHAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 500M 1B

2.3 Liquidity

EHAB has a Current Ratio of 1.46. This is a normal value and indicates that EHAB is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of EHAB (1.46) is comparable to the rest of the industry.
A Quick Ratio of 1.46 indicates that EHAB should not have too much problems paying its short term obligations.
EHAB has a Quick ratio of 1.46. This is comparable to the rest of the industry: EHAB outperforms 53.27% of its industry peers.
Industry RankSector Rank
Current Ratio 1.46
Quick Ratio 1.46
EHAB Yearly Current Assets VS Current LiabilitesEHAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for EHAB have decreased strongly by -52.08% in the last year.
EHAB shows a decrease in Revenue. In the last year, the revenue decreased by -1.11%.
EHAB shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.00% yearly.
EPS 1Y (TTM)-52.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-1.11%
Revenue growth 3Y-1%
Revenue growth 5YN/A
Sales Q2Q%-1.82%

3.2 Future

EHAB is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -8.68% yearly.
Based on estimates for the next years, EHAB will show a small growth in Revenue. The Revenue will grow by 4.45% on average per year.
EPS Next Y3.54%
EPS Next 2Y16.44%
EPS Next 3Y18.99%
EPS Next 5Y-8.68%
Revenue Next Year-1.03%
Revenue Next 2Y1.26%
Revenue Next 3Y2.41%
Revenue Next 5Y4.45%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
EHAB Yearly Revenue VS EstimatesEHAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M 1B
EHAB Yearly EPS VS EstimatesEHAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 35.39, the valuation of EHAB can be described as expensive.
EHAB's Price/Earnings ratio is in line with the industry average.
EHAB's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 29.63.
With a Price/Forward Earnings ratio of 27.29, EHAB can be considered very expensive at the moment.
The rest of the industry has a similar Price/Forward Earnings ratio as EHAB.
EHAB's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.68.
Industry RankSector Rank
PE 35.39
Fwd PE 27.29
EHAB Price Earnings VS Forward Price EarningsEHAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

63.55% of the companies in the same industry are more expensive than EHAB, based on the Enterprise Value to EBITDA ratio.
95.33% of the companies in the same industry are more expensive than EHAB, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 7.43
EV/EBITDA 12.67
EHAB Per share dataEHAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as EHAB's earnings are expected to grow with 18.99% in the coming years.
PEG (NY)9.99
PEG (5Y)N/A
EPS Next 2Y16.44%
EPS Next 3Y18.99%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EHAB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ENHABIT INC

NYSE:EHAB (2/21/2025, 8:15:24 PM)

After market: 8.14 0 (0%)

8.14

-0.3 (-3.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)03-05 2025-03-05/amc
Inst Owners101.3%
Inst Owner ChangeN/A
Ins Owners2.71%
Ins Owner Change3.42%
Market Cap409.28M
Analysts75
Price Target9.08 (11.55%)
Short Float %2.55%
Short Ratio4.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.98%
Min EPS beat(2)-22.31%
Max EPS beat(2)28.28%
EPS beat(4)3
Avg EPS beat(4)48.09%
Min EPS beat(4)-22.31%
Max EPS beat(4)123.41%
EPS beat(8)4
Avg EPS beat(8)7.87%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-4.69%
Min Revenue beat(2)-4.98%
Max Revenue beat(2)-4.4%
Revenue beat(4)0
Avg Revenue beat(4)-3.79%
Min Revenue beat(4)-4.98%
Max Revenue beat(4)-1.79%
Revenue beat(8)0
Avg Revenue beat(8)-4.2%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.89%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-17.99%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.58%
Valuation
Industry RankSector Rank
PE 35.39
Fwd PE 27.29
P/S 0.39
P/FCF 7.43
P/OCF 7.03
P/B 0.72
P/tB N/A
EV/EBITDA 12.67
EPS(TTM)0.23
EY2.83%
EPS(NY)0.3
Fwd EY3.66%
FCF(TTM)1.1
FCFY13.46%
OCF(TTM)1.16
OCFY14.22%
SpS20.63
BVpS11.26
TBVpS-8.98
PEG (NY)9.99
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.94%
ROE -20.6%
ROCE 3.35%
ROIC 2.65%
ROICexc 2.75%
ROICexgc 31.36%
OM 3.75%
PM (TTM) N/A
GM 48.79%
FCFM 5.31%
ROA(3y)-0.53%
ROA(5y)N/A
ROE(3y)-3.22%
ROE(5y)N/A
ROIC(3y)5%
ROIC(5y)N/A
ROICexc(3y)5.05%
ROICexc(5y)N/A
ROICexgc(3y)57.67%
ROICexgc(5y)N/A
ROCE(3y)6.32%
ROCE(5y)N/A
ROICexcg growth 3Y-35.07%
ROICexcg growth 5YN/A
ROICexc growth 3Y-24.78%
ROICexc growth 5YN/A
OM growth 3Y-27.36%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.9%
GM growth 5YN/A
F-Score4
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 0.89
Debt/FCF 9.54
Debt/EBITDA 7.16
Cap/Depr 9.9%
Cap/Sales 0.3%
Interest Coverage 0.85
Cash Conversion 82.91%
Profit Quality N/A
Current Ratio 1.46
Quick Ratio 1.46
Altman-Z 1.44
F-Score4
WACC8.77%
ROIC/WACC0.3
Cap/Depr(3y)52.67%
Cap/Depr(5y)39.82%
Cap/Sales(3y)1.63%
Cap/Sales(5y)1.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-52.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y3.54%
EPS Next 2Y16.44%
EPS Next 3Y18.99%
EPS Next 5Y-8.68%
Revenue 1Y (TTM)-1.11%
Revenue growth 3Y-1%
Revenue growth 5YN/A
Sales Q2Q%-1.82%
Revenue Next Year-1.03%
Revenue Next 2Y1.26%
Revenue Next 3Y2.41%
Revenue Next 5Y4.45%
EBIT growth 1Y-22.66%
EBIT growth 3Y-28.08%
EBIT growth 5YN/A
EBIT Next Year128.68%
EBIT Next 3Y35.46%
EBIT Next 5YN/A
FCF growth 1Y-40.17%
FCF growth 3Y28.22%
FCF growth 5YN/A
OCF growth 1Y-41.27%
OCF growth 3Y24.8%
OCF growth 5YN/A